SCHEMBL4877102

SCHEMBL4877102

CCCOc1ccc2ccccc2c1[C]=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
CNR1 P21554 4/20 0.51
CNR2 P34972 4/20 0.51
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TSHR P16473 1/20 0.47
PLA2G1B P04054 1/20 0.46
HSP90AA1 P07900 1/20 0.46
ATG4B Q9Y4P1 1/20 0.46
HTR1B P28222 5/20 0.43
CYP2C9 P11712 1/20 0.43
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
HTR1D P28221 2/20 0.42
TLR8 Q9NR97 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
MCHR1 Q99705 1/20 0.40
CA9 Q16790 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7420976 0.90 GAA (0.55) GAATDP1L3MBTL1CNR1CNR2
SCHEMBL2119647 0.87 ALOX5 (0.47) GAATDP1L3MBTL1TSHR
SCHEMBL6917366 0.84 CNR1 (0.48) GAATDP1L3MBTL1CNR1CNR2
SCHEMBL7309402 0.79 GAA (0.55) GAATDP1L3MBTL1CNR1CNR2
SCHEMBL3081463 0.78 MAPT (0.58) MEN1KMT2ACYP2C9
SCHEMBL2048172 0.78 MAPT (0.58) GAATDP1L3MBTL1CNR1CNR2
SCHEMBL2703781 0.77 GAA (0.53) GAATDP1L3MBTL1CNR1CNR2
SCHEMBL2096657 0.77 GAA (0.53) GAATDP1L3MBTL1CNR1CNR2
SCHEMBL6913432 0.76 GAA (0.52) GAATDP1L3MBTL1CNR1CNR2
SCHEMBL8394282 0.76 CNR1 (0.51) GAATDP1L3MBTL1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275095-A1 Combination of Prostaglandin E2 Receptor Antagonists and Renin-Angiotensin System Inhibitors for Treating Renal Diseases ASTELLAS PHARMA INC. (JP) 2008-11-06 US disclosed
EP-1742662-A2 COMBINATION OF PROSTAGLANDIN E2 RECEPTOR ANTAGONISTS AND RENIN-ANGIOTENSIN SYSTEM INHIBITORS FOR TREATING RENAL DISEASES Astellas Pharma Inc. (JP) 2007-01-17 EP disclosed
WO-2005105147-A2 COMBINATION OF PROSTAGLANDIN E2 RECEPTOR ANTAGONISTS AND RENIN-ANGIOTENSIN SYSTEM INHIBITORS FOR TREATING RENAL DISEASES ASTELLAS PHARMA INC. (JP) 2005-11-10 WO disclosed
US-6437146-B1 MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-08-20 US disclosed
EP-1115712-A1 OXAZOLE COMPOUNDS AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-07-18 EP disclosed
WO-2000018744-A1 OXAZOLE COMPOUNDS AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-06 WO disclosed
WO-1999015524-A1 THIAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275095-A1 Combination of Prostaglandin E2 Receptor Antagonists and Renin-Angiotensin System Inhibitors for Treating Renal Diseases AGTR2, REN, AGTR1 GAA 845/4885TDP1 4767/4885L3MBTL1 4856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.